Potentiation of aminoglycoside antibiotic activity using the body fat from the snake *Boa constrictor*

Felipe S. Ferreira,*1 Nalba L. G. Silva,2 Edinardo F. F. Matias,3 Samuel V. Brito,1 Francisco G. Oliveira,3 José G. M. Costa,3 Henrique D. M. Coutinho,3 Waltécio O. Almeida,3 Rômulo R. N. Alves3

1Departamento de Sistemática e Ecologia, Programa de Pós-graduação em Ciências Biológicas (Zoologia), Universidade Federal da Paraíba, Brazil, 2Departamento de Biologia, Universidade Estadual da Paraíba, Brazil, 3Departamento de Química Biológica, Universidade Regional do Cariri, Brazil.

Abstract: *Boa constrictor* is widely used in traditional communities in many different folk remedies and products derived from it are sold in public markets throughout northeastern Brazil and as its body fat has many different therapeutic indications as a folk remedy. The present work evaluates the antibacterial activity of the body fat from the snake *Boa constrictor* when employed either alone or in combination with antibiotics and discusses the ecological implications of the use of this traditional remedy. Oil (OBC) was extracted from body fat located in the ventral region of *B. constrictor* using hexane as a solvent. The antibacterial activity of OBC was tested against standard as well as multi-resistant lines, either alone and in combination with antibiotics. OBC did not demonstrate any relevant antibacterial activity against standard or multidrug-resistant bacterial strains. OBC showed synergistic activity when combined with the aminoglycoside antibiotics. Our results indicate that the body fat of *Boa constrictor* does not possess bactericidal activity, from the clinical point of view, but when combined with an antibiotic, the fat demonstrated a significant synergistic activity.

Keywords: antibacterial activity *Boa constrictor* snake synergistic activity traditional medicine zootherapy

Introduction

Biodiversity has been a source of products for the treatment of diseases, and thus, people have developed various practices and techniques to exploit biodiversity, accumulating a broad knowledge of the therapeutic and medicinal properties of animals, plants and minerals, which represent important alternatives in the substitution of allopathic medications (Kursar et al., 2007; Alves, 2009).

Animals and products derived from them, are essential ingredients in the preparation of many traditional remedies and have probably been used since prehistoric times (Lev, 2003; Silva et al., 2004; Almeida, 2007; Ferreira et al., 2009a,b). Alves (2008) documented the use of at least 290 different animal species used in folk medicine in Brazil, with *Boa constrictor* (Linnaeus, 1758) being frequently sought after in many different regions of that country (Costa-Neto, 1999; Alves et al., 2007a,b; 2009).

*B. constrictor*, Boidae, is a snake that can reach a mean length of 3.5 m; it has an arboreal habit but can display terrestrial habits; and it shows nocturnal and diurnal activity (Vanzolini et al., 1980). This snake feeds on mammals, birds and lizards (Henderson et al., 1995). It is found in neotropical areas (Mexico, Central America and South America, Antilles, and Dominica and St. Lucia islands). *B. constrictor* snakes are viviparous, and generally, copulation occurs in the fall up to the beginning of winter. Litter size can vary from 18 to 41 offspring (Peters et al., 1986).

*B. constrictor* is widely used in traditional communities in many different folk remedies (Costa-Neto, 2000; Andrade & Costa-Neto, 2006; Alves et al., 2007b; Alves et al., 2008; Alves, 2008; Alves et al. 2009a), and products derived from it are sold in public markets throughout northeastern Brazil (Alves & Rosa 2007a).

The most widely used zootherapeutic product derived from *B. constrictor* is its fat (Alves, 2009). Among the various applications attributed to this oil are treatments for the following ailments: rheumatism, lung
Potentiation of aminoglycoside antibiotic activity using the body fat from the snake Boa constrictor
Felipe S. Ferreira et al.

Many of the illnesses treated with products obtained from B. constrictor are associated with bacterial infections, which suggests that they may contain antibacterial components, but no laboratory studies evaluating the efficiency of this popular remedy have yet been undertaken.

There has been increasing attention paid to animals, both vertebrates and invertebrates, as sources of new medicines (Chivian, 2000). Animals have been methodically tested by pharmaceutical companies as sources of drugs for modern medical science (Cox, 1990), and the current percentage of animal sources for producing essential medicines is quite significant (Alves & Rosa, 2007a). Hunt & Vicent (2006) and Mayer & Gustafson (2008) stated that faunistic resources have been tested for the production and/or isolation of bioactive compounds. Rashid et al. (2009) isolated and purified polysaccharides from the sponge Celtodoryx girardei that possess an important antiviral activity against Herpes simplex. Stankevicius et al. (2008) evaluated the anti-mutagenic activity of extracts of the sponge Arenosclera brasiliensis. Barros et al. (2007) isolated a type of heparin from the ascidia of Styela plicata with a potent anesthetic activity.

On the other hand, studies have pointed to the inefficacy of some products utilized in traditional medicine in the treatment of some diseases and/or symptoms. Ferreira et al. (2009c) showed that the body fat of Tupinambis merianae does not inhibit bacterial growth, and thus it is not recommended for the treatment of diseases involving earache or infection. Of nearly 25,000 applications for registering traditional medicines that were examined by Malaysian authorities, for example, 37.3% were rejected based on considerations of either their safety or efficiency (Ang & Lee, 2006). These results indicate the necessity of evaluating the biological activity of natural products utilized in traditional medicine.

Studies on traditional uses of animal-derived resources must be coupled to considerations of conservation biology and public health policies; however, for the sustainable management of natural resources that have been highlighted by bio-prospecting, such studies are of primal importance for their sustainable use (Alves, 2009; Ferreira et al., 2009b).

The present work evaluates the antibacterial activity of the body fat of Boa constrictor when employed either alone or in combination with antibiotics and discusses the ecological implications of the use of this traditional remedy.

Materials and Methods

Zoological material

Specimen of Boa constrictor were collected in the municipality of Crato (7º 14' 03" S x 39º 24' 34" W), Ceará State, Brazil during the month of November 2009. The animals were anesthetized with ketamine (50 mg/mL), sacrificed to remove their body fat, and their remains deposited in the Laboratório de Zoologia da Universidade Regional do Cariri (LZ-URCA 0676).

Preparation of the oil from Boa constrictor (OBC)

Oil was extracted from the body fat located in the ventral region of the snake. Extraction was undertaken for four hours in a Soxhlet apparatus using hexane as the solvent. After the mixture was decanted and filtered, the oil was dried in a water-bath at 70 ºC for 2 h and subsequently stored in a freezer pending further analyses. A test solution of purified fat was prepared from 10 mg of the frozen sample dissolved in 1 mL of dimethylsulfoxide (Merck, Darmstadt, Germany), yielding an initial concentration of 10 mg/mL; this solution was then further diluted to 1024 µg/mL.

Strains

Experiments were performed with clinical isolates of Escherichia coli (EC27), resistant to low levels of neomycin and gentamicin, as well as to tobramycin, amikacin and kanamycin; and with isolates of Staphylococcus aureus 358 (SA358) resistant to several aminoglycosides (Freitas et al., 1999; Coutinho et al., 2005). The EC-ATCC25922 strain of Escherichia coli, the SA- ATCC12692 strain of Staphylococcus aureus, the PV-ATCC 13315 strain of Proteus vulgaris and the PA- ATCC 15442 strain of Pseudomonas aeruginosa were used as positive controls and were maintained on heart infusion agar slants (HIA, Difco). Prior to the assays, the cells were grown overnight at 37 ºC in brain heart infusion (BHI, Difco).

Drugs

Gentamicin, kanamycin, amikacin, neomycin were obtained from Sigma Chemical Corp., St. Louis, MO, USA. All of the drugs were dissolved in sterile water before use.
**Drug susceptibility test**

The minimum inhibitory concentrations (MIC) of the putative OBC antibiotics were determined in BHI by microdilution assays using suspensions of $10^5$ cfu/mL and drug concentrations ranging from 1 to 1024 µg/mL (in two-fold serial dilutions) (Javadpour et al., 1996). MIC was defined as the lowest drug concentration at which no bacterial growth was observed. For the evaluation of extracts and fractions as modulator of antibiotic activity, the MIC of the antibiotics were determined in the presence of each extract and fraction (32 µg/mL) at sub-inhibitory concentrations, and the plates were incubated for 24 h at 37 °C.

EC27 and SA358 strain were tested by the microdilution checkerboard technique (Elipolopoulos & Moellering, 1991). In order to evaluate the activity of combinations of drugs (amikacin and neomycin), fractional inhibitory concentration (FIC) indices were calculated as FIC_A + FIC_B, where FIC_A and FIC_B represent the minimum concentrations that inhibited the bacterial growth for drugs A and B, respectively: FIC_A = MIC_A combination/ MIC_A alone and FIC_B = MIC_B combination/ MIC_B alone. FIC index was interpreted as follows: synergistic (<0.5), additive (0.5-1), indifferent (>1) or antagonistic (>4).

**Results**

OBC did not demonstrate any relevant antibacterial activity against standard or multidrug-resistant bacterial strains (Table 1), demonstrating that there is no pharmacological basis for the use of these zootherapeutic products as an antibiotic for the treatment of diseases such as earache or sore throat generally caused by bacteria.

**Table 1.** Minimum inhibitory concentrations (MIC) of body fat from snake *Boa constrictor* (OBC) against standard or multidrug-resistant bacterial strains (µg/mL).

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>EC27 MIC</th>
<th>SA358 MIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBC</td>
<td>512</td>
<td>512</td>
</tr>
<tr>
<td>OBC+Amikacin</td>
<td>512</td>
<td>-</td>
</tr>
<tr>
<td>OBC+Neomycin</td>
<td>512</td>
<td>-</td>
</tr>
</tbody>
</table>

OBC was tested for bactericidal activity, against multidrug-resistant strains, when combined with an antibiotic (Table 2). OBC showed synergistic activity when combined with the aminoglycoside antibiotics with exception of kanamycin for EC27, and gentamicin for SA358. The results indicate the effectiveness of the use of body fat of *B. constrictor* in combination with antibiotics for the treatment of diseases caused by bacteria. With respect to tests of antibiotic-modifying activity, the results obtained show the OBC has marked modulatory activity when combined with aminoglycoside antibiotics. In the assays carried out with EC27, OBC synergism was observed with all antibiotics except kanamycin. The MIC of amikacin, neomycin and gentamicin against EC27 were 156, 625 and 19.5 µg/mL, respectively. However, when these antibiotics were combined with 32 µg/mL OBC, the MIC decreased to 4.9, 4.9 and 2.4 µg/mL, respectively (Table 2). In the assays carried out with SA358, there was no synergism with the combination of gentamicin and OBC. The MIC of kanamycin, amikacin and neomycin against SA358 were 312.5 µg/mL, but when the antibiotics were combined with OBC, the MIC decreased to 4.9, 2.4 and 2.4 µg/mL, respectively (Table 2). These are the first data on the drug-modulating activity *B. constrictor* against bacterial strains.

**Table 2. Minimum inhibitory concentrations (MIC) of body fat from snake *Boa constrictor* (OBC) against multidrug-resistant bacterial strains alone and combined with aminoglycosides (µg/mL).**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>EC27 MIC (µg/mL)</th>
<th>OBC+Antibiotic MIC (µg/mL)</th>
<th>SA358 MIC (µg/mL)</th>
<th>OBC+Antibiotic MIC (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBC</td>
<td>512</td>
<td>-</td>
<td>512</td>
<td>-</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>1250</td>
<td>1250</td>
<td>312.5</td>
<td>4.9</td>
</tr>
<tr>
<td>Amikacin</td>
<td>4.9</td>
<td>312.5</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Neomycin</td>
<td>4.9</td>
<td>312.5</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>4.9</td>
<td>4.9</td>
<td>4.9</td>
<td>4.9</td>
</tr>
</tbody>
</table>

The checkboard test showed additive and synergistic effect of the OBC when combined with amikacin and neomycin against EC27 and SA358 (Table 3). About the checkboard test, a combination of OBC and amikacin against EC27 showed a FIC_I = 0.5, while a combination of OBC and neomycin showed a FIC_I = 1. Both aminoglycoside antibiotics tested presented an additive effect. A combination of OBC/amikacin and OBC/neomycin against SA358 showed a FIC_I = 0.25 demonstrating a synergistic effect.

**Table 3. Minimum inhibitory concentrations (MIC) of body fat from snake *Boa constrictor* (OBC) and the effect of combinations with amikacin and neomycin.**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>EC 27 FIC index (type of interaction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBC/Amikacin</td>
<td>≥1024/16 (additive)</td>
</tr>
<tr>
<td>OBC/Neomycin</td>
<td>≥1024/64 (additive)</td>
</tr>
<tr>
<td>OBC/Neomycin</td>
<td>SA 358 (additive)</td>
</tr>
<tr>
<td>OBC/Amikacin</td>
<td>≥1024/32 (synergistic)</td>
</tr>
<tr>
<td>OBC/Neomycin</td>
<td>≥1024/32 (synergistic)</td>
</tr>
</tbody>
</table>

**Discussion**

The search for new pharmaceuticals derived from natural products has intensified in recent years (Kong et
Potentiation of aminoglycoside antibiotic activity using the body fat from the snake Boa constrictor
Felipe S. Ferreira et al.

al., 2009). Harvey (2008) reported that 225 drugs from natural sources were in developmental stages and, of these, 24 had been extracted from animals. The search for medicines and genes from nature has been promoted as a non-destructive use of habitat that promotes human health as well as supporting economic development and conservation (Kursar et al., 2007).

The present study showed the inefficacy of OBC, from the clinical point of view, against diseases caused by bacteria when applied alone. The lowest inhibitory concentration of OBC was 256 µg/mL against the strain P. vulgaris. For the other bacterial strains, the MIC of OBC was 512 µg/mL. These concentrations are considered ineffective, because a very high dose would be necessary to reach such concentration in plasma (Houghton et al., 2007). Falodum et al. (2008) evaluated the bactericidal activity of B. constrictor fat against bacteria S. aureus, B. subtilis, Streptococcus spp, E. coli and P. aeruginosa utilizing diffusion disks. In this work, the authors stated that the body fat of B. constrictor possesses antibacterial activity. However, the method utilized does not make it possible to determine a concentration at which the fat inhibits bacterial growth, as can be determined using a serial dilution method (Hadacek & Greger, 2000). Therefore, antibacterial activity can be indicated but not compared with the data obtained in this work.

Fatty acids can show antibacterial activity, mainly the unsaturated ones, by affecting the endogenous synthesis of bacterial fatty acids (Zheng et al., 2005). Body fat of B. constrictor contains 62 and 38% of unsaturated and saturated fatty acids, respectively. The composition of OBC was as follows: myristic acid, palmitic acid, stearic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, arachidonic acid (McCue, 2008).

Os results obtained for Boa constrictor differ from those obtained for other reptiles. For example, Ferreira et al. (2009c) evaluated the modulatory activity of the fat of Tupinambis merianae against bacterial strains. The results indicate that T. merianae fat did not increase the effectiveness of aminoglycosides against the bacterial strains tested. The MIC of amikacin and neomycin combined with body fat of T. merianae demonstrated no potentiation of those antibiotics against either E. coli or S. aureus. Both of the aminoglycosides tested (kanamycin and gentamicin) demonstrated a reduction in their effectiveness against E. coli or S. aureus when combined with body fat of T. merianae. A possible explanation would be the percentage of unsaturation observed between these fats, where the greater percentage of unsaturated fats was found in OTM.

Various products from animals have been tested against bacteria showing effective biological activity. Bosch et al. (2009) identified and isolated the peptide called hydramacine-1 from Hydra with antibacterial activity. Li et al. (2009) isolated a new sesquiterpene quinone from the sponge Dysidea villosa, with potential anti-bacterial activity. Adhya et al. (2009) isolated the lectin, molecular mass of 47 kDa, from the bivalve Macoma birmanica, which inhibited the growth of Gram-positive and Gram-negative bacteria. Stow & Beattie (2008) reviewed the defense mechanisms of social insects against microorganisms and stated that some of these compounds such as terpenoids and peptides can be utilized in medicine in the fight against pathogenic bacteria. Two proteins obtained from Branchiostoma belcheri demonstrated bactericidal activity (Fan et al., 2008; Ju et al. 2009). Wang et al. (2009) isolated a protein (hepcidine) of immune system of the fish Pseudosciaena crocea demonstrating antibacterial and antifungal activity. Conlon et al., (2006) reported on peptides of the japonicine-2 type with antibacterial activity from extracts of the skin of the frog Rana chaochaoensis. Park et al. (2009) isolated a protein of the lactoforicine type from Bos taurus milk with activity against bacteria.

Few works have shown antibiotic-modifying activity for zootherapeutic products. Coutinho et al. (2009; 2010) reported on the activities of decoctions of Nasutitermes corniger (“cupim”) against multidrug resistant bacteria. In that study, the decoctions showed synergistic activity when combined with neomycin.

Chin et al. (2006) stated that 87% of the categories of diseases that affect humans can be treated with natural products. Alves et al. (2007a, b) and Alves et al. (2009a) have warned about the potential for over exploitation of natural resources used by traditional medical practitioners. Hunt & Vincent (2006) warned that bioprospecting natural resources for the production of new pharmaceuticals could result in the over-exploitation of biodiversity, with direct and negative impacts on those sources. Various species of animals utilized in traditional medicine are threatened by extinction and are openly commercialized. There is no information on the biological activity of these resources, but their trafficking is common (Alves & Rosa, 2005, 2007c).

Servheen (1999) believes that fourteen species of bears, on the IUCN list, are commercialized in and outside of China for medicinal use. In Brazil, Alves et al. (2009b) listed a total of 44 reptile species used for medicinal or magic/religious purposes, and 23 (52.3%) are considered to be threatened with extinction. Pharmacological tests of products derived from animals threatened by extinction is of extreme importance, because validating or not this practice and proposing measures for rational and sustainable use are indispensable for the maintenance of the species (Albuquerque et al., 2009; Alves et al., 2009b). The case of the rhinoceros is an example. The use of rhinoceros horn in traditional medicine has been pointed out as the principal cause of the decline in the population of these animals.
(Lee, 1999). Although zootherapeutic products from this species have some proven value, as demonstrated by the work of But et al. (1990), who found substantial anti-pyretic activity in rhinoceros horn, the impact of such uses on the natural populations of these animals should be better analyzed, and alternative therapeutics should be considered. Many different reptiles are used by humans for many different purposes, such as foods, medicines, or as pets. Alves et al., (2009b) listed nine reptile species (including B. constrictor) that are used in Brazil for both food and medicinal purposes. While Brazilian law prohibits the commercialization of wild animals, whole animals or their parts can easily be found being sold in public markets for different purposes (Alves & Pereira-Filho 2007, Alves et al. 2007a). The multiple human uses of these animals represent an additional source of environmental pressure on this species, although the precise degree of impact will need to be more closely evaluated and contextualized (Alves & Rosa 2006, Alves et al. 2007b, Alves et al. 2009b).

As pointed out by McMichael & Beaglehole (2000), many of today’s public health issues have their roots in the same socioeconomic inequalities and imprudent consumption patterns that jeopardize the future sustainability of health. There is a need to promote conservation and to protect species utilized for medicinal purposes considering all the potential of these species, because bioprospecting is one of the incentives for the conservation of species (Kursar et al., 2007).

This situation demonstrates the importance of developing more detailed studies focusing on the interactions between humans and reptiles in order to be able to evaluate the true implications of the use of these animals for medicinal purposes and to develop viable strategies for their conservation (Ferreira et al., 2009c).

The hunting and sale of wild animals, including B. constrictor, is prohibited in Brazil. However, the commercial use of these animals as pets is possible by breeding the snakes in captivity, thereby reducing the pressure on wild populations (Marešová & Frynta, 2008). According to Alves et al. (2009b), a viable proposal might be the creation of cooperatives in rural communities to breed these reptiles for the medicinal and magic/religious markets. These cooperatives could breed any number of reptile species for commercial purposes with the appropriate authorization and regulation of governmental agencies and the guidance of specialists in the area (biologists, veterinarians and zootechnicians).

In view of the above, strategies for the rational use of products of B. constrictor should be idealized for the conservation this species. We also recommend that governmental environmental and health agencies intensify their control over the commercialization of products derived from animals in public markets, considering the indiscriminant commercial use of native species for medicinal purposes has been cited as one of the probable causes of the population declines noted in many plant and animal species (Alves & Rosa, 2005, 2007a,b).

Conclusions

Our results indicate that the body fat of Boa constrictor does not possess bactericidal activity, from the clinical point of view, but when combined with an antibiotic, the fat demonstrated a significant synergistic activity. The use and sale of products derived from Boa constrictor can tend to exert pressure on the wild populations of this species. Therefore, we recommend the following measures: i) development of management plans for a sustainable and rational use of this species, reducing the possible pressure on this species; and ii) more studies focusing on the use of body fat of Boa constrictor in the treatment of other illnesses.

Acknowledgements

The authors would like to thank the CAPES for the scholarships to FSF, SVB and the Funicap for the scholarships to EFFM and for support to Waltécio O. Almeida and José G. M. Costa (processo BPI-0112-2.05/08); IBAMA for collecting permission (007/ 2007 - CGFAP/IBAMA 02007.001009/2004) Many thanks to A. Leiva for reviewing the manuscript.

References


Lev E 2003. Traditional healing with animals (zootherapy); medieval to present-day Levantine practice. *J Ethnopharmacol* 85: 107-118.


McCue MD 2008. Fatty acid analyses may provide insight into the progression of starvation among squamate reptiles. *Comp Biochem Physiol 151*: 239-246.


*Correspondence*

Felipe S. Ferreira
Departamento de Sistemática e Ecologia, Centro de Ciências Exatas e da Natureza, Universidade Federal da Paraíba
Campus I, 58051-900 João Pessoa-PB, Brazil
Email address: ferreira_fs@dse.upb.br